Engflag

Sinopren

Quick links to important sections

Sinopren

Sinopren_DE

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Cardioprotective, Hypotensive, Natriuretic, Nephroprotective, Vasodilator

Treatment option: Hyperlipidemia, Hypertension, Diabetic Kidney Disease, Cerebrovascular Accident, Smoking, Nephropathy, Smoking Cessation, Diabetes Mellitus, Heart Failure, Heart Attack

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinopren

Quick Facts

Property Description
Active Ingredient (INN) Lisinopril dihydrate
Form Immediate-release oral tablet
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common Use Management of high blood pressure (hypertension)
Origin / Status Chemically synthesized, Prescription-Only

Sinopren: A Concise Introduction and Pharmacological Class

Sinopren is a prescription-only oral medicine containing Lisinopril, a compound that belongs to the pharmacological class of Angiotensin-Converting Enzyme (ACE) Inhibitors. This medicine is clinically recognized as a first-line therapy for the long-term management of elevated blood pressure.

As an ACE inhibitor, Sinopren works by regulating a key hormonal pathway in the body, ensuring blood vessels remain relaxed and open. This action is supported by pharmacological studies and makes Lisinopril a frequent choice for sustained circulatory support. Lisinopril is a non-prodrug, meaning it is biologically active immediately upon absorption without requiring the liver to process it first.

Composition and General Therapeutic Purpose

Sinopren is supplied as an immediate-release tablet for oral administration, with the active ingredient being Lisinopril dihydrate. The tablet formulation is specifically designed to dissolve efficiently for prompt absorption, which is a crucial feature for a medication intended for a once-daily dosing regimen.

The general therapeutic purpose of Sinopren is to regulate systemic blood pressure to reduce the overall workload on the heart and arteries. ACE inhibitors are recognized as critical tools in comprehensive cardiovascular care. These therapeutic principles relate to the medicine's role in protecting vital organs from the potential long-term damage associated with pressure overload. A typical neutral use scenario for Sinopren is its inclusion in a long-term treatment plan for adults diagnosed with mild to moderate hypertension.

Regulatory References

  1. NIH Review on ACE Inhibitors
  2. European Medicines Agency (EMA)

What side effects are possible with Sinopren?

Possible side effects and safety information

The safety profile for Sinopren, which contains the active substance Lisinopril, is formally classified by frequency and the physiological systems affected, based strictly on government regulatory documents.

Adverse Reaction Scope

Category Description (Based on Regulatory Labeling)
Key adverse reaction categories Effects on the cardiovascular, nervous, respiratory, renal, and gastrointestinal systems.
Frequency classification Common reactions (headache, cough, dizziness, diarrhoea, vomiting, hypotension). Uncommon reactions (mood alterations, rash, palpitations). Rare and Very Rare events are also documented.
System-organ classes involved Vascular Disorders, Respiratory Disorders, Nervous System Disorders, Gastrointestinal Disorders, Immune System Disorders, Renal/Urinary Disorders.
Serious adverse reactions Angioedema (swelling of the face, tongue, and throat), Symptomatic Hypotension, Acute Renal Failure, and Hepatic Failure are serious adverse reactions documented in regulatory sources.

Population-Specific Safety Constraints

The medicine is absolutely contraindicated for use during the second and third trimesters of pregnancy due to the risk of fetal injury. For individuals with renal impairment, the official label requires periodic monitoring of renal function, reflecting the drug’s potential impact on the kidneys. Additionally, the risk of excessively low blood pressure (hypotension) is noted to occur more frequently upon the initiation of therapy or when a dose increase is made, a time-related safety pattern described in the official label.

Regulatory Safety Summary

The safety structure emphasizes that while many effects are Common, events like angioedema and fetal toxicity are classified as serious concerns, with specific restrictions against use in patients with a history of ACE inhibitor-related angioedema. This classification method ensures transparent communication of the medicine's risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

A Sinopren (Lisinopril) overdose is documented in official prescribing information as primarily presenting with profound hypotension, which is an excessive lowering of blood pressure. Other documented clinical manifestations include cardiac effects such as tachycardia or bradycardia, systemic signs like dizziness and anxiety, and respiratory signs such as hyperventilation. Overdose may quickly escalate to severe, life-threatening outcomes, including circulatory shock and acute renal failure, and potential electrolyte disturbances like hyperkalemia.

Immediate medical intervention is required for any known or suspected overdose. Seek emergency medical attention immediately, and contact emergency services if the individual collapses, has a seizure, or experiences difficulty breathing. The official regulatory profile mandates hospital monitoring for at least 24 hours for all symptomatic or hypotensive patients. There is no specific antidote known for Lisinopril overdose. Supportive management described in regulatory documents includes the intravenous administration of normal saline solution and procedures such as haemodialysis to assist in drug removal. Caution is noted for volume-depleted patients and older adults due to increased risk of severe outcomes.

Therapeutic Uses of Sinopren

What Sinopren Treats: Main Uses and Benefits

Sinopren is prescribed to address specific conditions within the cardiovascular system. Its established clinical uses include managing mild to moderate high blood pressure (hypertension), used as a supportive agent for congestive heart failure alongside diuretics, and managing stable patients following an acute myocardial infarction (heart attack).

A primary application of the medication is to support the management of elevated blood pressure. In clinical scenarios, this medication is a common component in comprehensive strategies for cardiovascular health. This information is consistent with standard clinical data regarding this drug class.

“Achieving recommended blood pressure levels is an important aspect of cardiovascular care.”

Quick Fact: Relief for High Blood Pressure Sinopren assists in the management of elevated blood pressure.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sinopren?

Official regulatory labeling defines specific populations who are eligible, restricted, or absolutely prohibited from using Sinopren (Lisinopril).

Mandatory Exclusions (Contraindications)

Sinopren must not be used by patients with a history of angioedema (severe swelling) related to any previous ACE inhibitor or those with hereditary angioedema. It is absolutely contraindicated during pregnancy due to the risk of fetal toxicity and must be discontinued immediately if pregnancy is detected. Use is also prohibited in patients with diabetes receiving aliskiren or those who have taken a neprilysin inhibitor within 36 hours, as these combinations are expressly contraindicated.

Approved and Restricted Populations

The medicine is approved for use in adults for hypertension and related heart conditions. For children, it is approved from 6 years of age for hypertension, but only if they have adequate kidney function (GFR 30 mL/min/1.73 m^2). Use is not recommended in children under 6 or in breastfeeding women. Patients with severe renal impairment, hepatic impairment, or specific cardiovascular conditions (e.g., aortic stenosis) require special caution and monitoring due to population-specific restrictions documented in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction information for Sinopren, based on authoritative government regulatory sources.

Contraindicated and Restricted Combinations

The following combinations are strictly restricted or contraindicated due to documented safety concerns:

  • Neprilysin Inhibitors (e.g., sacubitril): Use is contraindicated. A 36-hour washout period is mandatory when switching between Sinopren and a neprilysin inhibitor-containing product due to increased angioedema risk.
  • Aliskiren: Contraindicated in patients with diabetes due to heightened risks of hypotension, hyperkalaemia, and renal dysfunction. Avoid use in patients with moderate to severe renal impairment (GFR <60 mL/min).

Other Clinically Significant Interactions

Interacting Substance/Class Documented Interaction Effect Constraint Context
Diuretics (e.g., Thiazides) Additive lowering of blood pressure. May lead to symptomatic hypotension.
Potassium-Increasing Agents (e.g., K-sparing diuretics, Heparin) Increased risk of hyperkalaemia (elevated serum potassium). Requires close monitoring of serum potassium levels.
Lithium Increased systemic exposure of lithium, leading to toxicity risk. Serum lithium concentrations must be monitored closely during concomitant use.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Potential for reduced effectiveness of Sinopren and increased risk of worsening renal function. Use with caution, particularly in the elderly or those with existing volume depletion or renal compromise.

Procedural and Timing Notes

Caution is advised when Sinopren is used with antidiabetic medicines (insulin, oral agents) due to the potential for an enhanced blood-glucose-lowering effect. Caution is also necessary during anaesthesia/surgery, as Sinopren may potentiate the hypotensive effects of anaesthetic agents.

Mechanism of Action

Sinopren: Molecular Mechanism of Action

Sinopren functions as a selective small molecule inhibitor that primarily targets the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANK-L) pathway. Its activity involves the direct binding and neutralization of soluble and membrane-bound RANK-L.

By binding to RANK-L, Sinopren prevents its interaction with the RANK receptor found on the surface of pre-osteoclasts. This blockade disrupts the necessary signaling for the differentiation and maturation of osteoclasts (osteoclastogenesis), effectively modulating the downstream intracellular processes activated by this pathway.

The resulting disruption of the RANK/RANK-L interaction and the subsequent inhibition of osteoclast formation lead to a measurable reduction in the overall number and activity of bone-resorbing osteoclasts. This physiological consequence is restricted to the cellular level of bone metabolism.

Dosage and Administration Information

How to use Sinopren

The usage of Sinopren, an immediate-release oral tablet, is defined by clinical parameters that dictate its route, frequency, and dose adjustments for specific patient populations. The administration is intended for long-term management of chronic conditions, or a minimum course of six weeks following an acute myocardial infarction. The dose is consistently taken once daily at approximately the same time each day, with flexibility to be taken either with or without food.

Feature Clinical Administration Guidelines
Route & Timing Oral administration, once daily, independent of meal times.
Standard Dosing Hypertension: Initial dose is typically 10 mg daily, advancing to a usual maintenance range of 20 mg to 40 mg once daily. Heart Failure: Initial dosing begins lower, at 2.5 mg to 5 mg once daily.
Dose Titration Dosage adjustments are made in a stepwise manner, generally at intervals of 1 to 4 weeks, up to the maximum dose.
Renal Adjustments Patients with impaired renal function require a lower initial dose; for instance, the starting dose is halved for patients with a creatinine clearance (CrCl) between 10 and 30 mL/min.
Pediatric Use For children aged 6 and older, administration is based on body weight, starting at 0.07 mg/kg once daily (initial maximum 5 mg).
Initiation Condition The very first dose, particularly in high-risk scenarios such as post-myocardial infarction or heart failure, is recommended to be administered under close medical supervision.
Missed Dose Rule Should a dose be missed, it should be taken as soon as possible, unless it is almost time for the next scheduled dose, in which case the subsequent dose is taken as scheduled, without doubling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sinopren

Evidence for use in High Blood Pressure Management (Hypertension)

Research exploring Sinopren's use in high blood pressure management was studied for its use in affecting blood pressure measurements. The evidence base relies on extensive, large-scale Randomized Controlled Trials (RCTs). These studies often tracked long-term cardiovascular outcomes related to physiological strain or stress, such as the occurrence of stroke and myocardial infarction.

Findings describe patterns observed in the studies regarding blood pressure measurements in the observed populations. Trials also monitored research exploring long-term patterns in the occurrence rates of major cardiovascular events. Research examined outcomes related to kidney function, particularly in patients who also presented with chronic kidney disease (CKD).

Evidence as a Supportive Agent for Congestive Heart Failure

The use of Sinopren in heart failure was evaluated in major, dedicated clinical trials. These studies primarily focused on adults with symptomatic heart failure who had a documented reduced ejection fraction (HFrEF). The research explored long-term, critical endpoints, including rates of all-cause mortality and the frequency of heart failure-related hospitalizations.

Studies reported specific data points regarding all-cause mortality and the proportion of participants requiring re-hospitalization due to heart failure exacerbation. Observed changes in patient function, such as shifts in their NYHA functional class, were a frequently reported outcome. Data are still emerging for patients whose heart failure involves a preserved ejection fraction (HFpEF), where the evidence base is limited compared to that for HFrEF.

What is Still Uncertain About Sinopren: Research Gaps and Limitations

The evidence base contains several documented limitations. Subgroup findings are uncertain for specific ethnic or racial groups and for patients with complex comorbidities who were generally not included in large numbers in the initial RCTs. Comparative evidence is lacking for some of the direct, head-to-head comparisons against every possible alternative medicine. Furthermore, The assessment of secondary or exploratory outcomes reflects variability across studies. The research provides context but evidence highlights what is known — and what is still uncertain — particularly for long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Sinopren (FAQ)

Q: Does it make you sleepy?

A: Official regulatory documents, such as the full product information, indicate that certain central nervous system effects are reported as potential adverse reactions. These reported effects can include somnolence (sleepiness) or dizziness. Regulatory bodies and official product information usually include a complete listing of possible side effects; patients are encouraged to review this full information.

Q: Is it safe long-term?

A: Regulatory documents and official studies focus on the safety and efficacy of Sinopren during clinical trials, which often cover a specific, defined time period. According to this official information, the long-term safety and effectiveness of the medicine for use exceeding that duration, such as longer than six or twelve months, may not have been fully established or extensively evaluated. When using the medication over a prolonged period, patients should discuss the available data with a healthcare professional.

How should Sinopren be stored and disposed of?

How to Store and Dispose of Sinopren?

The storage of Sinopren (Lisinopril tablets) is strictly defined by regulatory requirements to ensure product quality.

Storage Conditions

Sinopren must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with excursions permitted up to 30 C. It is mandatory to protect the tablets from moisture and excessive heat, and they must not be frozen. The medication must be dispensed and stored in a tight container. As a critical safety rule, keep Sinopren out of the reach of children.

Disposal Instructions

Official disposal guidelines recommend using a drug take-back program for unused or expired tablets. If a take-back option is unavailable, the product should be mixed with an undesirable substance, such as coffee grounds, sealed in a bag or container, and placed in household trash. All identifying information on the prescription label must be removed prior to discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Africa

Equivalent of Sinopren found in:

A-Z Index: